International Clinical Trial: Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07362017) titled 'Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis' on Jan. 20.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Vanda Pharmaceuticals

Condition: Moderate-to-severe Chronic Plaque Psoriasis

Intervention: Drug: Ponesimod

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: January 2026

Target Sample Size: 300

To know more, visit https://clinicaltrials.gov/study/NCT07362017

Disclaimer: Curated...